<DOC>
	<DOCNO>NCT00630539</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety tolerability Ospemifene 5 mg , 15 mg , 30 mg treatment VVA postmenopausal woman find minimum effective dose low dose 30 mg test earlier Phase II .</brief_summary>
	<brief_title>A Clinical Study Evaluate Efficacy Safety Ospemifene Treatment Vulvar Vaginal Atrophy ( VVA ) Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Naturally surgically menopausal Vaginal pH great 5.0 5 % few superficial cell maturation index vaginal smear Evidence endometrial hyperplasia , cancer pathology Abnormal PAP smear Uterine bleed unknown origin uterine polyp Current vaginal infection require medication Use hormonal medication Clinically significant abnormal gynecological finding sign vaginal atrophy</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Menopausal symptom</keyword>
	<keyword>Urogenital atrophy</keyword>
	<keyword>Vulvar vaginal atrophy postmenopausal woman</keyword>
	<keyword>Vaginal atrophy</keyword>
</DOC>